A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA VP of Policy Featured in Citybiz on Launch of New Center for Public Policy
In a new piece published by citybiz, OCRA’s Vice President, Policy, Chad Ramsey, discusses the launch of OCRA’s Center for Public Policy, highlighting its role in expanding critical advocacy work and bringing more agency to the gynecologic cancer community. Ramsey explains how patient, survivor, and caregiver experiences have helped shape OCRA’s advocacy priorities over the past … Continued
OCRA’s Advocate’s Corner: December 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance As 2025 ends, we’re reflecting on a year marked by growth, resilience, and meaningful impact. In a complex policy environment, one thing remained constant: the dedication of OCRA’s advocates to advancing policies that strengthen care, access, and support for people impacted by ovarian and gynecologic … Continued
OCRA’s Advocate’s Corner: November 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance Federal Update: Government Shutdown Ends — What It Means for the Cancer Community As you are no doubt aware, after 43 days, the federal government shutdown officially ended. On November 12, 2025, President Donald J. Trump signed the temporary funding bill passed by Congress, reopening … Continued